FLT3-ITD微克隆对接受强化疗的年轻成人急性髓系白血病患者的预后影响
该研究对Backbone Intergroup 1试验中1733例新诊断AML患者进行事后分析,用NGS检测FLT3-ITD微克隆(AR 0.0004–0.05)。无宏克隆患者中17.4%存在微克隆,微克隆与宏克隆均独立增加复发风险,2年累积复发率微克隆组达45.1%,挑战现行风险分层。
要点
- NGS可检出AR低至0.0004的FLT3-ITD微克隆,无宏克隆患者中占17.4%。
- 微克隆独立增加复发风险(cause-specific HR 1.50),2年累积复发率45.1%。
- 诊断时微克隆患者41.8%的复发伴随宏克隆出现,支持将NGS检测纳入诊疗流程。
核心结论
- FLT3-ITD微克隆与宏克隆均独立增加AML复发风险,挑战现行风险分层模型。
- 在NPM1突变AML中,微克隆和宏克隆与更高MRD水平和复发风险相关,校正MRD后对总生存无独立影响。
- 诊断时存在微克隆的患者中,41.8%的复发伴随宏克隆出现。
研究设计与样本
- Backbone Intergroup 1试验(NCT02416388)的事后分析,纳入1733例新诊断AML患者。
- 采用下一代测序(NGS)检测FLT3-ITD微克隆,定义AR在0.0004至0.05之间。
主要发现
- 无FLT3-ITD宏克隆的患者中,17.4%检出微克隆。
- 校正年龄、白细胞计数、其他基因突变、midostaurin治疗和异基因造血干细胞移植后,微克隆、低AR宏克隆和高AR宏克隆的cause-specific HR分别为1.50(95%CI 1.18-1.91)、1.98(1.50-2.62)和2.33(1.69-3.22)。
- 2年累积复发率:宏克隆组42.5%(95%CI 37.0-47.9),微克隆组45.1%(38.3-51.6),无FLT3-ITD组29.4%(26.6-32.3)。
临床怎么用
- 支持将基于NGS的FLT3-ITD检测整合入AML诊断和预后评估流程。
- 微克隆患者的管理需前瞻性试验探索,并应考虑纳入未来欧洲白血病网(ELN)指南。
局限性
- 为事后分析,微克隆患者的管理尚缺乏前瞻性试验证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
FLT3 internal tandem duplications (FLT3-ITD) are major genetic events in acute myeloid leukemia (AML). Although the clinical impact of FLT3-ITD "macroclones" (allelic ratio [AR] ≥0.05) is well established, the significance of low-level FLT3-ITD subclones ("microclones") remains uncertain. We conducted a post hoc analysis of 1733 patients with newly diagnosed AML enrolled in the Backbone Intergroup 1 trial (ClinicalTrials.gov identifier: NCT02416388). Using next-generation sequencing (NGS), we detected FLT3-ITD microclones (AR between 0.0004 and 0.05) in 17.4% of patients without FLT3-ITD macroclones. Microclones and macroclones (low and high AR) were independently associated with increased relapse risk (cause-specific hazard ratio, 1.50 [95% confidence interval (CI), 1.18-1.91]; 1.98 [1.50-2.62]; and 2.33 [1.69-3.22], respectively) after adjustment for age, white blood cell count, other gene mutations, midostaurin treatment, and allogeneic hematopoietic stem cell transplantation. At 2 years, the cumulative incidence of relapse reached 42.5% (95% CI, 37.0-47.9) in patients with macroclones, 45.1% (38.3-51.6) in patients with microclones, and 29.4% (26.6-32.3) in patients without FLT3-ITD. In NPM1-mutated AML, both microclones and macroclones were associated with higher levels of measurable residual disease (MRD) and increased relapse risk, without independent impact on overall survival after adjustment for MRD. An analysis of paired samples further revealed that 41.8% of relapses in patients with FLT3-ITD microclones at diagnosis were associated with a macroclone at relapse. These findings challenge current risk stratification models and support the integration of NGS-based FLT3-ITD detection into the diagnostic and prognostic workflow for AML. Prospective trials addressing the management of patients with FLT3-ITD microclones are warranted, as is their consideration in future European LeukemiaNet guidelines.
引用
- Duployez N, Joudinaud R, Boudry A, et al. Prognostic impact of FLT3-ITD microclones in young adults with acute myeloid leukemia treated with intensive chemotherapy. Blood. 2026. PMID: 42166362. doi:10.1182/blood.2025032829
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。